Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
Hoher Wachstum
Der Umsatz des Unternehmens ist in den letzten 3 Jahren stetig gewachsen und beträgt im Durchschnitt 22.41% im Jahr.
Wachstum
Das Unternehmen befindet sich in einer Wachstumsphase, wobei das aktuelle Jahreseinkommen insgesamt 41.70M USD beträgt.
Unterbewertet
Die aktuelle PE1 des Unternehmens liegt bei -1.042, im niedrigen 3-Jahres-Perzentilbereich.
Institutionelle Verkäufe
Die neuesten institutionellen Bestände sind 2.75M Aktien, was einen Rückgang von 9.14% im Vergleich zum Vorquartal darstellt.